1.Predictive values of general movements qulity assessment and amplitude-integrated electroencephligram in motor development outcomes of neonates with severe hyperbilirubinemia
Fei YAN ; Li XU ; Hua MEI ; Yan ZHANG ; Kang SUN ; Xiufeng NIU
Chinese Pediatric Emergency Medicine 2024;31(7):523-526
Objective:To explore the early predictive value of amplitude-integrated electroencephalogram(aEEG) combined with general movements(GMs)assessment for motor development outcomes in infants with severe hyperbilirubinemia at 12 months of age.Methods:The clinical data of 125 cases of neonates with severe hyperbilirubinaemia admitted to the NICU at Inner Mongolia Medical University Hospital from January 2020 to June 2022 were retrospectively analyzed.The aEEG were performed within 24 h of admission;GMs assessment were carried out at the duration of hospital stay,when the serum bilirubin values decreased below phototherapy intervention value and the infant was stable. The patients were regularly followed-up until one-year-old to evaluate the predictive values by Griffiths Developmental Scale.Results:A total of 125 infants with severe hyperbilirubinemia were enrolled,including 82(65.6%)males and 73(58.4%)females,with the mean gestational age of(38.1±1.5)weeks,the mean birth weight of(3 169±573)g,and the mean serum bilirubin of(378.5±51.9)μmol/L. Of the 125 infants diagnosed by Griffiths assessment at the age of 12 months,normal in 86 cases(68.8%),and abnormal in 39 cases(31.2%). GMs writhing phase assessment had a sensitivity of 100%, negative predictive value of 100% and specificity of 19.77% in predicting motor developmental outcome in neonates with severe hyperbilirubinaemia. The aEEG had a sensitivity of 92.31% and a negative predictive value of 94.92% in predicting motor developmental outcome in neonates with severe hyperbilirubinaemia, with a higher specificity of 65.12%. The sensitivity and negative predictive value of aEEG+GMs assessment for predicting motor developmental outcome in neonates with severe hyperbilirubinaemia were 87.18% and 92.42%, respectively, with the highest specificity of 70.93%.Conclusion:GMs writhing stage assessment, aEEG assessment, and aEEG combined with GMs early assessment have good predictive value for motor developmental outcomes in neonates with severe hyperbilirubinaemia.The aEEG combined with GMs assessment has a high specificity, which can improve the predictive effect of motor developmental outcomes in neonates with hyperbilirubinaemia.
2.Chinese expert consensus on refined diagnosis,treatment,and management of advanced primary liver cancer(2023 edition)
Liu XIUFENG ; Xia FENG ; Chen YUE ; Sun HUICHUAN ; Yang ZHENGQIANG ; Chen BO ; Zhao MING ; Bi XINYU ; Peng TAO ; Ainiwaer AIZIER ; Luo ZHIWEN ; Wang FUSHENG ; Lu YINYING ; National Clinical Research Center for Infectious Diseases ; Society of Hepatology,Beijing Medical Association ; Translational Medicine Branch,China Association of Gerontology and Geriatrics
Liver Research 2024;8(2):61-71
Hepatocellular carcinoma(HCC),commonly known as primary liver cancer,is a major cause of malignant tumors and cancer-related deaths in China,accounting for approximately 85%of all cancer cases in the country.Several guidelines have been used to diagnose and treat liver cancer.However,these guidelines provide a broad definition for classifying advanced liver cancer,with an emphasis on a singular approach,without considering treatment options for individual patients.Therefore,it is necessary to establish a comprehensive and practical expert consensus,specifically for China,to enhance the diagnosis and treatment of HCC using the Delphi method.The classification criteria were refined for Chinese patients with HCC,and the corresponding optimal treatment regimen recommendations were developed.These recommendations took into account various factors,including tumor characteristics,vascular tumor thrombus grade,distant metastasis,liver function status,portal hypertension,and the hepatitis B virus replication status of patients with primary HCC,along with treatment prognosis.The findings and rec-ommendations provide detailed,scientific,and reasonable individualized diagnosis and treatment strategies for clinicians.
3.Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma
Xinrong YANG ; Huichuan SUN ; Qing XIE ; Wanguang ZHANG ; Weidong JIA ; Ming ZHAO ; Haitao ZHAO ; Xiufeng LIU ; Ledu ZHOU ; Sheng YAN ; Li XU ; Nanya WANG ; Yuan DING ; Xiaodong ZHU ; Jian ZHOU ; Jia FAN
Chinese Journal of Digestive Surgery 2023;22(2):167-180
Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4,2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.
4.Study of the inflammatory activating process in the early stage of Fusobacterium nucleatum infected PDLSCs.
Yushang WANG ; Lihua WANG ; Tianyong SUN ; Song SHEN ; Zixuan LI ; Xiaomei MA ; Xiufeng GU ; Xiumei ZHANG ; Ai PENG ; Xin XU ; Qiang FENG
International Journal of Oral Science 2023;15(1):8-8
Fusobacterium nucleatum (F. nucleatum) is an early pathogenic colonizer in periodontitis, but the host response to infection with this pathogen remains unclear. In this study, we built an F. nucleatum infectious model with human periodontal ligament stem cells (PDLSCs) and showed that F. nucleatum could inhibit proliferation, and facilitate apoptosis, ferroptosis, and inflammatory cytokine production in a dose-dependent manner. The F. nucleatum adhesin FadA acted as a proinflammatory virulence factor and increased the expression of interleukin(IL)-1β, IL-6 and IL-8. Further study showed that FadA could bind with PEBP1 to activate the Raf1-MAPK and IKK-NF-κB signaling pathways. Time-course RNA-sequencing analyses showed the cascade of gene activation process in PDLSCs with increasing durations of F. nucleatum infection. NFκB1 and NFκB2 upregulated after 3 h of F. nucleatum-infection, and the inflammatory-related genes in the NF-κB signaling pathway were serially elevated with time. Using computational drug repositioning analysis, we predicted and validated that two potential drugs (piperlongumine and fisetin) could attenuate the negative effects of F. nucleatum-infection. Collectively, this study unveils the potential pathogenic mechanisms of F. nucleatum and the host inflammatory response at the early stage of F. nucleatum infection.
Humans
;
Fusobacterium nucleatum/metabolism*
;
NF-kappa B/metabolism*
;
Periodontal Ligament/metabolism*
;
Signal Transduction
;
Fusobacterium Infections/pathology*
;
Stem Cells/metabolism*
5.Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer.
Juanjuan FENG ; Zhengke LIAN ; Xinting XIA ; Yue LU ; Kewen HU ; Yunpeng ZHANG ; Yanan LIU ; Longmiao HU ; Kun YUAN ; Zhenliang SUN ; Xiufeng PANG
Acta Pharmaceutica Sinica B 2023;13(3):1145-1163
MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative phosphorylation (OXPHOS) induction as a profound metabolic alteration to confer KRAS-mutant non-small cell lung cancer (NSCLC) resistance to the clinical MEK inhibitor trametinib. Metabolic flux analysis demonstrated that pyruvate metabolism and fatty acid oxidation were markedly enhanced and coordinately powered the OXPHOS system in resistant cells after trametinib treatment, satisfying their energy demand and protecting them from apoptosis. As molecular events in this process, the pyruvate dehydrogenase complex (PDHc) and carnitine palmitoyl transferase IA (CPTIA), two rate-limiting enzymes that control the metabolic flux of pyruvate and palmitic acid to mitochondrial respiration were activated through phosphorylation and transcriptional regulation. Importantly, the co-administration of trametinib and IACS-010759, a clinical mitochondrial complex I inhibitor that blocks OXPHOS, significantly impeded tumor growth and prolonged mouse survival. Overall, our findings reveal that MEK inhibitor therapy creates a metabolic vulnerability in the mitochondria and further develop an effective combinatorial strategy to circumvent MEK inhibitors resistance in KRAS-driven NSCLC.
6.Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma
Xinrong YANG ; Huichuan SUN ; Qing XIE ; Wanguang ZHANG ; Weidong JIA ; Ming ZHAO ; Haitao ZHAO ; Xiufeng LIU ; Ledu ZHOU ; Sheng YAN ; Li XU ; Nanya WANG ; Yuan DING ; Xiaodong ZHU ; Jian ZHOU ; Jia FAN
Chinese Journal of Hepatology 2023;31(10):1018-1029
Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4, 2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.
7.Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy.
Jiulong ZHANG ; Xiaoyan SUN ; Xiufeng ZHAO ; Chunrong YANG ; Menghao SHI ; Benzhuo ZHANG ; Haiyang HU ; Mingxi QIAO ; Dawei CHEN ; Xiuli ZHAO
Acta Pharmaceutica Sinica B 2022;12(9):3694-3709
Amplifying "eat me signal" during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary "eat me signal" for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy. Doxorubicin (DOX), ATP and ferrous ions (Fe2+) were co-assembled into nanosized amplifier (ADO-Fe) through π‒π stacking and coordination effect. Meanwhile, phenylboric acid-polyethylene glycol-phenylboric acid (PBA-PEG-PBA) was modified on the surface of ADO-Fe (denoted as PADO-Fe) by the virtue of d-ribose unit of ATP. PADO-Fe could display active targetability against tumor cells via sialic acid/PBA interaction. In acidic microenvironment, PBA-PEG-PBA would dissociate from amplifier. Moreover, high H2O2 concentration would induce hydroxyl radical (·OH) and oxygen (O2) generation through Fenton reaction by Fe2+. DOX and ATP would be released from the amplifier, which could induce ICD effect and "ICD adjuvant" to amplify this process. Together with programmed death ligands 1 (PD-L1) checkpoint blockade immunotherapy, PADO-Fe could not only activate immune response against primary tumor, but also strong abscopal effect against distant tumor. Our simple and multifunctional ICD amplifier opens a new window for enhancing ICD effect and immune checkpoint blockade therapy.
8.Mechanism of action of Jieduhuayu granules for remission of oxidative stress in hepatocytes
Rongzhen ZHANG ; Dewen MAO ; Kewei SUN ; Xiufeng WANG ; Yin LIU ; Tingshuai WANG ; Yanmei LAN
Chinese Journal of Hepatology 2021;29(12):1188-1193
Objective:To study and explore the effect and mechanism of action of Jieduhuayu granules on oxidative injury of human liver L02 cells.Methods:Human liver L02 oxidative injury model was established with 0.1 mmol/ L H 2O 2 intervention for 1 h, and treated with different concentrations of Jieduhuayu (JDHY) solution. Hepatocytes were divided into five groups: normal, H 2O 2, H 2O 2 + JDHY (0.5 mg/ml), H 2O 2 + JDHY (1 mg/ml), and H 2O 2 + JDHY (1.5 mg/ml). MTT assay was used to detect hepatocytes activity. Transmission electron microscope was used to observe mitochondrial morphology in hepatocytes. Biochemical test was used to detect the levels of superoxide dismutase, lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, malondialdehyde, and reduced glutathione and albumin in hepatocytes. Western blot was used to detect the expression levels of rabbit anti-phosphatidylinositol 3-kinase (PI3K), AKT and mTOR in hepatocytes. One-way analysis of variance was used for comparison between multiple groups, and the LSD method was used for pairwise comparison. Results:Compared with the normal group, the cell proliferation activity ( P < 0.05), mitochondrial vacuolization, superoxide dismutase activity, reduced albumin and glutathione content, and PI3K, AKT, and mTOR protein expression levels in the H 2O 2 group were all significantly reduced ( P < 0.05), while the content of malondialdehyde and the activities of alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase were significantly increased ( P < 0.05). Compared with H 2O 2 group, the cell proliferation activity ( P < 0.05), alterations in morphological remission of mitochondria, superoxide dismutase activity, reduced albumin and glutathione content, and PI3K, AKT and mTOR protein expression levels in the H 2O 2 + JDHY (1 mg/ml) and H 2O 2 + JDHY (1.5 mg/ml) group ( P < 0.05) were all significantly increased ( P < 0.05), while malondialdehyde content and alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase activities were significantly decreased ( P < 0.05). Conclusion:Jieduhuayu granule can effectively improve oxidative stress and mitochondrial injury in hepatocytes, and its effect may be related to the promoting expression of PI3K/AKT/mTOR signaling pathways.
9.A consensus on the standardization of the next generation sequencing process for the diagnosis of genetic diseases (2)-Sample collection, processing and detection
Xiufeng ZENG ; Zhenpeng XU ; Hui HUANG ; Wubin QU ; Ian J WU ; Juan WANG ; Yong GAO ; Dongyan AN ; Xiaoqing WANG ; Hui XIONG ; Yiping SHEN ; Ming QI ; Xuxu DENG ; Xiong XU ; Lele SUN ; Zhiyu PENG ; Weihong GU ; Shangzhi HUANG ; Shihui YU
Chinese Journal of Medical Genetics 2020;37(3):339-344
With high accuracy and precision,next generation sequencing (NGS) has provided a powerful tool for clinical testing of genetic diseases.To follow a standardized experimental procedure is the prerequisite to obtain stable,reliable,and effective NGS data for the assistance of diagnosis and/or screening of genetic diseases.At a conference of genetic testing industry held in Shanghai,May 2019,physicians engaged in the diagnosis and treatment of genetic diseases,experts engaged in clinical laboratory testing of genetic diseases and experts from third-party genetic testing companies have fully discussed the standardization of NGS procedures for the testing of genetic diseases.Experts from different backgrounds have provided opinions for the operation and implementation of NGS testing procedures including sample collection,reception,preservation,library construction,sequencing and data quality control.Based on the discussion,a consensus on the standardization of the testing procedures in NGS laboratories is developed with the aim to standardize NGS testing and accelerate implementation of NGS in clinical settings across China.
10.Application value of nano-carbon tracer technique in the treatment of malignant tumors of pancreatic body and tail in radical antegrade modular pancreatosplenectomy
Shichang CUI ; Xiufeng LI ; Yang LIU ; Jiang WANG ; Jianxing YU ; Guang HAO ; Qidong SUN
International Journal of Surgery 2019;46(1):30-36,封4
Objective The application of nano-carbon tracer technique in radical antegrade modular pancreatosplenectomy (RAMPS) to treat malignant tumors of pancreatic body and tail.To investigate whether radical anterograde modulization of pancreatic body and tail combined with nano-carbon tracer technique is more beneficial to the prognosis of patients.Methods From January 2014 to September 2018,a retrospective analysis was performed in 48 patients in Linyi Central Hospital,all patients underwent RAMPS,all of whom were pathologically proved to be pancreatic carcinoma of the body and tail.Based on whether the nano-carbon lymph node tracer was performed during the operation,the patients were divided into two groups:nano-carbon group (nano-carbon lymph node tracing) and conventional operation group (no nano-carbon lymph node tracer).The differences between the two groups were analyzed,including operative time,intraoperative blood loss,postoperative complications (pancreatic fistula),postoperative hospitalization time,postoperative pathological lymph node status (number of dissection,number of positive lymph nodes,the positive rate of lymph node black staining in nano-carbon group) and survival time after operation.The measurement data were expressed as mean ± standard deviation (Mean ± SD),t-test were used for comparison among groups;Chi-square test was used for comparison of counting data,and Kaplan-Meier test was used for comparison of survival rate.Results There was no significant difference in the time of operation [(4.45 ± 0.59) h vs (4.41 ±0.65) h],the amount of blood lost during operation [(447.39 ± 109.51) ml vs (434.8 ± 76.38) ml] and the time of hospitalization after operation [(16.52 ± 4.12) d vs (16.56 ±2.92) d] between the two groups (P>0.05).There were 1 case of pancreatic fistula in the nano-carbon group and 2 cases of pancreatic fistula in the convertional operation group,but the difference was not statistically significant (P =0.55).The number of lymph nodes dissected and positive lymph nodes in nano-carbon group were significantly higher than those in conventional operation group [(18.26 ± 2.49) vs (12.16 ± 2.19);(5.52 ± 1.50) vs (3.32 ± 0.85).The difference was statistically significant (P < 0.05).The positive rate of lymph nodes in black stained lymph nodes (38.10%,96/252) was significantly higher than that in non-stained lymph nodes (18.45%,31/168),and the difference was statistically significant (P < 0.05).The average survival time in the nano-carbon group [(25.48 ± 11.74) months] was significantly longer than that in the conventional operation group [(15.80 ± 11.64) months],and the difference was statistically significant (P < 0.05).Conclusions It is safe,effective and feasible to treat malignant tumors of pancreatic body and tail by RAMPS combined with nano-carbon tracer technique.The positive rate of lymph node dissection and the detection rate of total lymph nodes are increased,and the prognosis of patients is improved,to improve the survival time of patients after operation is improved.

Result Analysis
Print
Save
E-mail